Compare Inovio Pharmaceuticals Inc (INO) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Yum! Brands, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Yum! Brands, Inc. trades at $144.69 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 347.8× Inovio Pharmaceuticals Inc's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Yum! Brands, Inc. for 132 Days on average.
| INO | YUM | |
|---|---|---|
Market Cap | $112.19M | $39.02B |
Volume | 3,201,278 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $168.16 |
52-Week Low | $0.66 | $135.77 |
Typical Hold Time | 43 Days | 132 Days |
Enterprise Value | $83.51M | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
YUM trades at $144.82, up 3.18% today, with a bullish technical signal despite mixed indicators. Revenue grew to $8.21B in 2025, with net income of $1.56B and a strong net margin of 25.4%. The company recently sold Pizza Hut for $1.5B and announced a $0.75 dividend, reflecting strategic focus on core brands. Analysts maintain a consensus price target of $170.44, with 39% buy ratings.
YUM presents a stable investment with consistent earnings beats and dividend growth, but faces risks from high debt levels and competitive pressures. Upside is supported by analyst targets and operational efficiency, while macroeconomic headwinds and consumer spending trends pose challenges to sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
